Paratek Pharmaceuticals Inc (NASDAQ:PRTK) rose 6.3% on Monday . The stock traded as high as $15.45 and last traded at $15.30. Approximately 509,128 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 499,913 shares. The stock had previously closed at $14.40.
PRTK has been the topic of several analyst reports. BidaskClub lowered shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 2nd. ValuEngine lowered shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Finally, Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Wednesday, January 10th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. Paratek Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $40.75.
The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $425.40, a price-to-earnings ratio of -4.55 and a beta of 0.40.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings data on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.03). Paratek Pharmaceuticals had a negative return on equity of 93.16% and a negative net margin of 706.00%. The company had revenue of $5.07 million for the quarter, compared to the consensus estimate of $5.00 million. research analysts forecast that Paratek Pharmaceuticals Inc will post -3.39 EPS for the current year.
In other Paratek Pharmaceuticals news, CFO Douglas W. Pagan sold 16,291 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $14.22, for a total transaction of $231,658.02. Following the sale, the chief financial officer now owns 39,570 shares of the company’s stock, valued at approximately $562,685.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert S. Radie sold 3,000 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $14.22, for a total transaction of $42,660.00. Following the sale, the director now directly owns 9,330 shares in the company, valued at approximately $132,672.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,664 shares of company stock worth $573,226. Insiders own 4.90% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Omni Partners LLP bought a new position in shares of Paratek Pharmaceuticals in the 3rd quarter valued at about $3,707,000. Alyeska Investment Group L.P. boosted its stake in shares of Paratek Pharmaceuticals by 473.4% in the 3rd quarter. Alyeska Investment Group L.P. now owns 916,349 shares of the specialty pharmaceutical company’s stock valued at $23,000,000 after purchasing an additional 756,535 shares during the last quarter. C WorldWide Group Holding A S boosted its stake in shares of Paratek Pharmaceuticals by 46.8% in the 3rd quarter. C WorldWide Group Holding A S now owns 645,100 shares of the specialty pharmaceutical company’s stock valued at $16,192,000 after purchasing an additional 205,700 shares during the last quarter. Davidson Kempner Capital Management LP bought a new position in shares of Paratek Pharmaceuticals in the 3rd quarter valued at about $6,727,000. Finally, State Street Corp boosted its stake in shares of Paratek Pharmaceuticals by 112.3% in the 2nd quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock valued at $14,850,000 after purchasing an additional 325,856 shares during the last quarter. 75.28% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Paratek Pharmaceuticals (PRTK) Stock Price Up 6.3%” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2018/03/12/paratek-pharmaceuticals-prtk-stock-price-up-6-3.html.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.